These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

372 related items for PubMed ID: 10470199

  • 1. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK).
    Wechsel HW, Petri E, Bichler KH, Feil G.
    Anticancer Res; 1999; 19(4A):2583-90. PubMed ID: 10470199
    [Abstract] [Full Text] [Related]

  • 2. The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma.
    Oremek GM, Teigelkamp S, Kramer W, Eigenbrodt E, Usadel KH.
    Anticancer Res; 1999; 19(4A):2599-601. PubMed ID: 10470201
    [Abstract] [Full Text] [Related]

  • 3. Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy.
    Nisman B, Yutkin V, Nechushtan H, Gofrit ON, Peretz T, Gronowitz S, Pode D.
    Urology; 2010 Aug; 76(2):513.e1-6. PubMed ID: 20573390
    [Abstract] [Full Text] [Related]

  • 4. Value of tumor M2 (Tu M2-PK) in patients with renal carcinoma.
    Oremek GM, Sapoutzis N, Kramer W, Bickeböller R, Jonas D.
    Anticancer Res; 2000 Aug; 20(6D):5095-8. PubMed ID: 11326675
    [Abstract] [Full Text] [Related]

  • 5. The pyruvate kinase isoenzyme M2 (Tu M2-PK) as a tumour marker for renal cell carcinoma.
    Weinberger R, Appel B, Stein A, Metz Y, Neheman A, Barak M.
    Eur J Cancer Care (Engl); 2007 Jul; 16(4):333-7. PubMed ID: 17587357
    [Abstract] [Full Text] [Related]

  • 6. Quantitative detection of tumor M2-PK in serum and plasma.
    Hugo F, Fischer G, Eigenbrodt E.
    Anticancer Res; 1999 Jul; 19(4A):2753-7. PubMed ID: 10470235
    [Abstract] [Full Text] [Related]

  • 7. Pre-analytical problems in the measurement of tumor type pyruvate kinase (tumor M2-PK).
    Oremek GM, Gerstmeier F, Sauer-Eppel H, Sapoutzis N, Wechsel HW.
    Anticancer Res; 2003 Jul; 23(2A):1127-30. PubMed ID: 12820359
    [Abstract] [Full Text] [Related]

  • 8. [Immunohistochemical demonstration of L- and M2-pyruvate kinase in primary renal cell carcinomas and their metastases].
    Fischer G, Holzrichter S, Reinacher M, Heinrichs M, Dembowski J, Eigenbrodt E.
    Verh Dtsch Ges Pathol; 1989 Jul; 73():422-7. PubMed ID: 2482632
    [Abstract] [Full Text] [Related]

  • 9. Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells.
    Eigenbrodt E, Reinacher M, Scheefers-Borchel U, Scheefers H, Friis R.
    Crit Rev Oncog; 1992 Jul; 3(1-2):91-115. PubMed ID: 1532331
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of the Pyruvate Kinase isoenzyme tumor (Tu M2-PK) as a tumor marker for cervical carcinoma.
    Kaura B, Bagga R, Patel FD.
    J Obstet Gynaecol Res; 2004 Jun; 30(3):193-6. PubMed ID: 15210041
    [Abstract] [Full Text] [Related]

  • 11. Quantification of tumor type M2 pyruvate kinase (Tu M2-PK) in human carcinomas.
    Eigenbrodt E, Basenau D, Holthusen S, Mazurek S, Fischer G.
    Anticancer Res; 1997 Jun; 17(4B):3153-6. PubMed ID: 9329624
    [Abstract] [Full Text] [Related]

  • 12. Value of tumor M2-PK in thyroid carcinoma: a pilot study.
    Bena-Boupda NF, Rezai SS, Klett R, Eigenbrodt E, Bauer R.
    Anticancer Res; 2003 Jun; 23(6D):5237-40. PubMed ID: 14981996
    [Abstract] [Full Text] [Related]

  • 13. Tumor M2-PK levels in haematological malignancies.
    Oremek GM, Rox S, Mitrou P, Sapoutzis N, Sauer-Eppel H.
    Anticancer Res; 2003 Jun; 23(2A):1135-8. PubMed ID: 12820361
    [Abstract] [Full Text] [Related]

  • 14. Thymidine kinase activity in serum of renal cell carcinoma patients is a useful prognostic marker.
    Luo P, He E, Eriksson S, Zhou J, Hu G, Zhang J, Skog S.
    Eur J Cancer Prev; 2009 Jun; 18(3):220-4. PubMed ID: 19282758
    [Abstract] [Full Text] [Related]

  • 15. Tumor type M2 pyruvate kinase expression in advanced breast cancer.
    Lüftner D, Mesterharm J, Akrivakis C, Geppert R, Petrides PE, Wernecke KD, Possinger K.
    Anticancer Res; 2000 Jun; 20(6D):5077-82. PubMed ID: 11326672
    [Abstract] [Full Text] [Related]

  • 16. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker.
    Kumar Y, Tapuria N, Kirmani N, Davidson BR.
    Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):265-76. PubMed ID: 17301655
    [Abstract] [Full Text] [Related]

  • 17. Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma.
    Gayed BA, Gillen J, Christie A, Peña-Llopis S, Xie XJ, Yan J, Karam JA, Raj G, Sagalowsky AI, Lotan Y, Margulis V, Brugarolas J.
    BMC Urol; 2015 Apr 03; 15():24. PubMed ID: 25885592
    [Abstract] [Full Text] [Related]

  • 18. Tumor type M2-pyruvate-kinase levels in pleural fluid versus plasma in cancer patients: a further tool to define the need for invasive procedures.
    Elia S, Massoud R, Guggino G, Cristino B, Cortese C, De Massimi AR, Zenobi R.
    Eur J Cardiothorac Surg; 2008 Apr 03; 33(4):723-7. PubMed ID: 18261916
    [Abstract] [Full Text] [Related]

  • 19. Pyruvate kinase isoenzyme M2 is not of diagnostic relevance as a marker for oral cancer.
    Ervens J, Fuchs H, Niemann VT, Hoffmeister B.
    J Craniomaxillofac Surg; 2008 Mar 03; 36(2):89-94. PubMed ID: 18243718
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.